170 related articles for article (PubMed ID: 37372439)
1. Lipid-Associated GWAS Loci Predict Antiatherogenic Effects of Rosuvastatin in Patients with Coronary Artery Disease.
Kononov S; Azarova I; Klyosova E; Bykanova M; Churnosov M; Solodilova M; Polonikov A
Genes (Basel); 2023 Jun; 14(6):. PubMed ID: 37372439
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Statistical and Bioinformatics Analysis in the Deciphering of Putative Mechanisms by Which Lipid-Associated GWAS Loci Contribute to Coronary Artery Disease.
Lazarenko V; Churilin M; Azarova I; Klyosova E; Bykanova M; Ob'edkova N; Churnosov M; Bushueva O; Mal G; Povetkin S; Kononov S; Luneva Y; Zhabin S; Polonikova A; Gavrilenko A; Saraev I; Solodilova M; Polonikov A
Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203469
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic loci for rosuvastatin are associated with intima-media thickness change and coronary artery disease risk.
Kononov S; Mal G; Azarova I; Klyosova E; Bykanova M; Churnosov M; Polonikov A
Pharmacogenomics; 2022 Jan; 23(1):15-34. PubMed ID: 34905955
[No Abstract] [Full Text] [Related]
4. Endothelial lipase genetic polymorphisms and the lipid-lowering response in patients with coronary artery disease on rosuvastatin.
Cai G; Zhang B; Shi G; Weng W; Yang L; Xue S
Lipids Health Dis; 2016 Sep; 15(1):148. PubMed ID: 27600285
[TBL] [Abstract][Full Text] [Related]
5. Effect of 2-year treatment with low-dose rosuvastatin on intima-media thickness in hypercholesterolemic subjects with asymptomatic carotid artery disease.
Riccioni G; Cipollone F; Santovito D; Scotti L; D'Orazio N; Mezzetti A; Bucciarelli T
Expert Opin Pharmacother; 2011 Dec; 12(17):2599-604. PubMed ID: 21999752
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of oral rosuvastatin intervention on HDL and its associated proteins in men with type 2 diabetes mellitus.
Naresh S; Bitla AR; Rao PVLNS; Sachan A; Amancharla YL
Endocrine; 2021 Jan; 71(1):76-86. PubMed ID: 32895874
[TBL] [Abstract][Full Text] [Related]
7. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
Crouse JR; Raichlen JS; Riley WA; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Bots ML;
JAMA; 2007 Mar; 297(12):1344-53. PubMed ID: 17384434
[TBL] [Abstract][Full Text] [Related]
8. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study.
Bots ML; Palmer MK; Dogan S; Plantinga Y; Raichlen JS; Evans GW; O'Leary DH; Grobbee DE; Crouse JR;
J Intern Med; 2009 Jun; 265(6):698-707. PubMed ID: 19298496
[TBL] [Abstract][Full Text] [Related]
9. [EFFICIENCY OF CONCOMITANT USE OF POLICOSANOL AND ROSUVASTATIN IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE AND MODERATE HEPATIC DYSFUNCTION].
Solomenchuk TM; Vosukh V; Bedzay A; Koval VG; Chepka IM; Trotsko VV
Lik Sprava; 2015; (7-8):29-37. PubMed ID: 27491147
[TBL] [Abstract][Full Text] [Related]
10. Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label).
Braamskamp MJAM; Langslet G; McCrindle BW; Cassiman D; Francis GA; Gagne C; Gaudet D; Morrison KM; Wiegman A; Turner T; Miller E; Kusters DM; Raichlen JS; Martin PD; Stein EA; Kastelein JJP; Hutten BA
Circulation; 2017 Jul; 136(4):359-366. PubMed ID: 28592434
[TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study.
Zheng H; Li H; Wang Y; Li Z; Hu B; Li X; Fu L; Hu H; Nie Z; Zhao B; Wei D; Karlson BW; Bots ML; Meng X; Chen Y; Wang Y;
Stroke; 2022 Oct; 53(10):3004-3013. PubMed ID: 36017704
[TBL] [Abstract][Full Text] [Related]
12. Rosuvastatin reduces intima-media thickness in hypercholesterolemic subjects with asymptomatic carotid artery disease: the Asymptomatic Carotid Atherosclerotic Disease in Manfredonia (ACADIM) Study.
Riccioni G; Bazzano LA; Bucciarelli T; Mancini B; di Ilio E; D'Orazio N
Expert Opin Pharmacother; 2008 Oct; 9(14):2403-8. PubMed ID: 18778179
[TBL] [Abstract][Full Text] [Related]
13. Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe.
Taylor AJ; Villines TC; Stanek EJ
Eur Heart J; 2012 Dec; 33(23):2939-45. PubMed ID: 22564353
[TBL] [Abstract][Full Text] [Related]
14. Impact of intensive lipid lowering on lipid profiles over time and tolerability in stable coronary artery disease: insights from a subanalysis of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS).
Kawashiri MA; Yamagishi M; Sakamoto T; Takayama T; Hiro T; Daida H; Hirayama A; Saito S; Yamaguchi T; Matsuzaki M;
Cardiovasc Ther; 2013 Dec; 31(6):335-43. PubMed ID: 23409830
[TBL] [Abstract][Full Text] [Related]
15. Indicators of the atherogenic lipoprotein phenotype measured with density gradient ultracentrifugation predict changes in carotid intima-media thickness in men and women.
Maki KC; Dicklin MR; Davidson MH; Mize PD; Kulkarni KR
Vasc Health Risk Manag; 2012; 8():31-8. PubMed ID: 22272073
[TBL] [Abstract][Full Text] [Related]
16. LDL-cholesterol to HDL-cholesterol ratio discordance with lipid parameters and carotid intima-media thickness: a cohort study in China.
Lou Y; Li X; Cao L; Qin P; Shi J; Zhang Y; Wang C; Ma J; Wang L; Peng X; Chen H; Xu S; Hu F; Zhao Y; Zhao P
Lipids Health Dis; 2020 Jun; 19(1):141. PubMed ID: 32552893
[TBL] [Abstract][Full Text] [Related]
17. Change in carotid intima-media thickness in a high-risk group of patients by intensive lipid-lowering therapy with rosuvastatin: subanalysis of the JART study.
Yokoi H; Nohara R; Daida H; Hata M; Kaku K; Kawamori R; Kishimoto J; Kurabayashi M; Masuda I; Sakuma I; Yamazaki T; Yoshida M
Int Heart J; 2014; 55(2):146-52. PubMed ID: 24632963
[TBL] [Abstract][Full Text] [Related]
18. Effect of garlic powder tablet on carotid intima-media thickness in patients with coronary artery disease: a preliminary randomized controlled trial.
Mahdavi-Roshan M; Zahedmehr A; Mohammad-Zadeh A; Sanati HR; Shakerian F; Firouzi A; Kiani R; Nasrollahzadeh J
Nutr Health; 2013 Apr; 22(2):143-55. PubMed ID: 25573347
[TBL] [Abstract][Full Text] [Related]
19. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: Justification for Atherosclerosis Regression Treatment (JART) study.
Nohara R; Daida H; Hata M; Kaku K; Kawamori R; Kishimoto J; Kurabayashi M; Masuda I; Sakuma I; Yamazaki T; Yokoi H; Yoshida M;
Circ J; 2012; 76(1):221-9. PubMed ID: 22094911
[TBL] [Abstract][Full Text] [Related]
20. Effect of Rosuvastatin on Cholesterol Efflux Capacity and Endothelial Function in Type 2 Diabetes Mellitus and Dyslipidemia.
Jung KY; Kim KM; Han SK; Yun HM; Oh TJ; Choi SH; Park KS; Jang HC; Lim S
Circ J; 2018 Apr; 82(5):1387-1395. PubMed ID: 28943594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
